Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Humacyte Coronary Tissue Engineered Vessel (CTEV), Humacyte Coronary Tissue Engineered Vessel
CTEV · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | EXPERIMENTAL | Surgically implanted CTEV for CABG |
| Name | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | BIOLOGICAL | The CTEV is a tissue-engineered acellular vascular conduit regulated as a biological product by the Food and Drug Administration (FDA). The CTEV has an inner diameter of 3.5 mm and with approximately 20 cm of usable length. |
Inclusion Criteria: 1. Age ≥18 years with the ability to provide written informed consent. 2. Planned first isolated CABG surgery for atherosclerotic coronary artery disease with a planned LIMA graft to the LAD and at least one other planned vessel bypass. 3. An RCA or LCx territory target vessel f...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
CTEV stands for Humacyte Coronary Tissue Engineered Vessel. It is an investigational product being developed by Humacyte, Inc. for patients with coronary artery disease who require coronary artery bypass grafting, or CABG. It is a tissue engineered vessel designed for use as a bypass conduit in that surgical setting.
CTEV is being studied for use in patients with coronary artery disease who require coronary artery bypass grafting, also called CABG. The investigational product is intended as a tissue engineered vessel for the bypass procedure. Its safety and efficacy in this population are being evaluated in a Phase 2 clinical trial.
CTEV is made by Humacyte, Inc., which trades on the Nasdaq under the ticker HUMA. Humacyte is developing the Coronary Tissue Engineered Vessel as an investigational product for coronary artery disease patients who need coronary artery bypass grafting.
CTEV is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 2 study is evaluating its safety and efficacy in patients with coronary artery disease requiring coronary artery bypass grafting.
CTEV is being studied in one Phase 2 trial, NCT07730528, titled a study to evaluate the safety and efficacy of Humacyte's Coronary Tissue Engineered Vessel in patients with coronary artery disease requiring coronary artery bypass grafting. The trial is not yet recruiting and plans to enroll 10 participants.
Yes. CTEV is an abbreviation for Humacyte Coronary Tissue Engineered Vessel. The full name and the acronym refer to the same investigational product developed by Humacyte, Inc. for patients with coronary artery disease who require coronary artery bypass grafting.